AB Science SA

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

20 сен 2021 13:15:45 Источник Nasdaq GlobeNewswire

AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

16 сен 2021 13:34:08 Источник Nasdaq GlobeNewswire

AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib

14 сен 2021 12:01:33 Источник Nasdaq GlobeNewswire

AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association

13 сен 2021 12:04:50 Источник Nasdaq GlobeNewswire

AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

02 сен 2021 11:59:01 Источник Nasdaq GlobeNewswire

AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

25 авг 2021 12:46:55 Источник Nasdaq GlobeNewswire

AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

23 авг 2021 13:43:09 Источник Nasdaq GlobeNewswire

AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib

19 авг 2021 11:51:36 Источник Nasdaq GlobeNewswire

AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders

06 авг 2021 13:02:25 Источник Nasdaq GlobeNewswire

AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC

29 июл 2021 12:06:56 Источник Nasdaq GlobeNewswire

AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)

22 июл 2021 12:10:35 Источник Nasdaq GlobeNewswire

AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

20 июл 2021 12:08:07 Источник Nasdaq GlobeNewswire

AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo

19 июл 2021 12:12:44 Источник Nasdaq GlobeNewswire

AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France

12 июл 2021 02:00:28 Источник Nasdaq GlobeNewswire

AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib

28 июн 2021 13:59:14 Источник Nasdaq GlobeNewswire

AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting

10 июн 2021 12:54:29 Источник Nasdaq GlobeNewswire

AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

08 июн 2021 02:30:40 Источник Nasdaq GlobeNewswire

AB Science will host a live webcast on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

02 июн 2021 09:32:44 Источник Nasdaq GlobeNewswire

AB Science announces a voluntary hold in the clinical studies of masitinib worldwide

01 июн 2021 00:59:55 Источник Nasdaq GlobeNewswire

AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer

26 май 2021 13:18:48 Источник Nasdaq GlobeNewswire